Skip to content
Life Sciences Series A Founded 2016

mRNA

Developer of therapeutics for the treatment of cancer, rare diseases, and others. Its proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. It applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. It has developed a…

📍 Gaithersburg, United States · Oncology,

Funding snapshot

Last roundSeries A
Amount$12M
Date29 March 2022
Total raised$12M
Team size9

About

Developer of therapeutics for the treatment of cancer, rare diseases, and others. Its proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. It applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. It has developed a synthetic biology-based, artificial intelligence-aided platform that helps to design b Founded in 2016, headquartered in Gaithersburg, United States. The company has raised $12.3M at the Series A stage backed by investors including TMCP, Sirnaomics, Rotating Boulder Fund, Shenzhen Hongtao Fund Management. Operating in Life Sciences > Oncology, Life Sciences > Infectious Diseases.

Business model

Oncology > Drugs > Diversified,

Infectious Diseases > Drugs > Diversified,

Rare Diseases > Drugs > Diversified,

Genomics > Applied Genomics > Synthetic Biology

Institutional investors

TMCP Sirnaomics Rotating Boulder Fund Shenzhen Hongtao Fund Management

Latest coverage

No articles yet.

Raising like mRNA?

Analyze your pitch deck before your next raise.

Analyze My Deck →